OncoMatch/Endometrial / Uterine Cancer/PIK3CA
Endometrial / Uterine CancerPIK3CA Clinical Trials
PIK3CA activating mutations are among the most frequent alterations in endometrial cancer (~50% of endometrioid subtype) and activate the PI3K/AKT/mTOR pathway, which is a central therapeutic axis in this disease. mTOR inhibitors (lenvatinib plus everolimus) and AKT inhibitors (capivasertib) have demonstrated activity in endometrial cancer. Trials evaluate PI3K/AKT/mTOR-directed combinations and biomarker-stratified approaches for pMMR endometrial cancer.
Top recruiting PIK3CA Endometrial / Uterine Cancer trials
Ranked by phase and US site count. See all 3 trials matched to your profile →
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Totus Medicines
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Browse other molecular targets with active Endometrial / Uterine Cancer trials.